Cargando…

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies

Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated with rapidly deteriorating kidney function. Liver transplantation remains the only curative treatment for decompensated cirrhosis. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curry, Michael P., Vargas, Hugo E., Befeler, Alex S., Pyrsopoulos, Nikolaos T., Patwardhan, Vilas R., Jamil, Khurram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827960/ https://www.ncbi.nlm.nih.gov/pubmed/36633470 http://dx.doi.org/10.1097/01.HC9.0000897228.91307.0c

Ejemplares similares

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
por: Wong, Florence, et al.
Publicado: (2022)

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
por: Karvellas, Constantine J., et al.
Publicado: (2023)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
por: Belcher, Justin M.
Publicado: (2023)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis
por: Wang, Haiqing, et al.
Publicado: (2018)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
por: Kim, Hae Rim, et al.
Publicado: (2013)

Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome
por: Chiang, Chi-Wen, et al.
Publicado: (2019)

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
por: Mohamed, Mohamed M G, et al.
Publicado: (2021)

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
por: Ayyad, Ahlam, et al.
Publicado: (2023)

Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India
por: Sudan, Sourav, et al.
Publicado: (2023)

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2013)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?
por: Altun, Reskan, et al.
Publicado: (2015)

The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin
por: Flamm, Steven L., et al.
Publicado: (2021)

Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
por: Huang, Xingyue, et al.
Publicado: (2023)

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence
por: Bai, Zhaohui, et al.
Publicado: (2020)

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies
por: Sanyal, A. J., et al.
Publicado: (2017)

In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V(1) and V(2)
por: Jamil, Khurram, et al.
Publicado: (2017)

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug
por: Thangaraj, Santhosh Raja, et al.
Publicado: (2023)

The Hepatorenal Syndrome Patient Pathway: Retrospective Analysis of Electronic Health Records
por: Jamil, Khurram, et al.
Publicado: (2022)

Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome
por: Abdel-Razik, Ahmed, et al.
Publicado: (2020)

Terlipressin or Europressin?
por: Leone, Marc
Publicado: (2009)

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study
por: Kulkarni, Anand V., et al.
Publicado: (2022)

Terlipressin-induced hyponatraemia
por: Gray, R, et al.
Publicado: (2014)

Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome
por: Wong, Florence, et al.
Publicado: (2019)

Terlipressin‐induced foot ischemia
por: Ata, Fateen, et al.
Publicado: (2020)

Rebound hypotension following terlipressin bolus infusion can be prevented by continuous low-dose infusion of terlipressin
por: Lange, M, et al.
Publicado: (2007)

Effects of terlipressin as early treatment for protection of brain in a model of haemorrhagic shock
por: Ida, Keila Kazue, et al.
Publicado: (2015)

Ramipril poisoning rescued by naloxone and terlipressin
por: Samanta, Samanta, et al.
Publicado: (2014)

Vasopressin and terlipressin in adult vasodilatory shock
por: Polito, Angelo, et al.
Publicado: (2012)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Hepatorenal Syndrome
por: Kiser, Tyree H.
Publicado: (2014)

Terlipressin in the treatment of catecholamine resistant septic shock
por: Auzinger, GM, et al.
Publicado: (2002)

Vasopressin vs Terlipressin in Treatment of Refractory Shock
por: Scarpati, G, et al.
Publicado: (2013)

Terlipressin-induced hyponatremic seizure in a child
por: Zaki, Syed Ahmed
Publicado: (2013)

Natural Products Improving Hyperuricemia with Hepatorenal Dual Effects
por: Hao, Shijun, et al.
Publicado: (2016)

Following the MAP for Improved Kidney Function in Hepatorenal Syndrome
por: Thau, Matthew R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m32cvr1jnrsavfqnfsiai5ulvp